AIDS Therapies

Cellular Fusion Inhibitors Show Promise

Published in Gene Therapy Weekly, February 1st, 2001

Recent research into the process of HIV cell fusion may lead to novel therapies for inhibiting or shutting down that process, researchers suggest in the journal Expert Opinion on Therapeutic Patents.

"Current anti-HIV therapies targeting reverse transcriptase and protease enzymes suffer from high cost, a high probability of engendering resistance, and adverse side effects following prolonged use," explained O.M.Z. Howard and colleagues at the U.S. National Cancer Institute in Maryland. "Thus, we are faced with the need to develop new antiviral strategies with more potent compounds and/or novel antiviral targets."

The success of other...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-02-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry